See the DrugPatentWatch profile for Vyepti
Vyepti is a medication used to prevent migraine headaches [1]. It is an intravenous (IV) infusion therapy [2].
What is Vyepti used for?
Vyepti is prescribed for the preventive treatment of episodic migraine in adults [1]. Migraine is a neurological condition characterized by recurrent headaches that can be moderate to severe [3]. Preventive treatment aims to reduce the frequency, severity, and duration of migraine attacks [4].
How does Vyepti work?
Vyepti's active ingredient is eptinezumab-aavb [1]. It is a calcitonin gene-related peptide (CGRP) antagonist. CGRP is a molecule that plays a role in migraine pathophysiology [5]. By blocking CGRP, Vyepti helps to prevent migraine attacks [5]. It is administered intravenously, meaning it is given directly into a vein [2].
When does Vyepti patent protection end?
Information regarding the specific patent expiration dates for Vyepti may be found on specialized databases. DrugPatentWatch.com tracks patent information for many medications, including their expiry dates [6].
Who makes Vyepti?
Vyepti is manufactured by Lundbeck, a global pharmaceutical company [1].
What are the potential side effects of Vyepti?
The most common side effects associated with Vyepti include upper respiratory tract infections and hypersensitivity reactions [1]. Hypersensitivity reactions can include rash and itching [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How is Vyepti administered and how often?
Vyepti is given as an intravenous infusion by a healthcare professional [2]. It is typically administered every three months [7]. The infusion process itself takes about 30 minutes [2].
How does Vyepti compare to other migraine prevention treatments?
Vyepti is one of several preventive migraine treatments available. Other treatment classes include oral medications such as beta-blockers, anticonvulsants, and antidepressants, as well as other CGRP-targeted therapies that are administered via injection [8]. The choice of treatment often depends on individual patient factors, including medical history, migraine characteristics, and treatment preferences [8].
What clinical data supports Vyepti's effectiveness?
Clinical trials have demonstrated Vyepti's efficacy in reducing monthly migraine days. In studies, patients receiving Vyepti experienced a significant decrease in the number of migraine days per month compared to those receiving a placebo [7]. The drug's effectiveness is generally assessed based on these reductions in migraine frequency [7].
What are the regulatory approvals for Vyepti?
Vyepti has received approval from regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for the preventive treatment of migraine in adults [1].
Are there alternatives to Vyepti for migraine prevention?
Yes, several alternative approaches exist for migraine prevention. These include oral medications with different mechanisms of action, other injectable CGRP inhibitors, and non-pharmacological interventions like biofeedback or cognitive behavioral therapy [8].
Sources:
[1] https://www.vyepti.com/
[2] https://www.vyepti.com/how-to-get-vyepti/how-it-works
[3] https://www.ninds.nih.gov/health-information/disorders/headache
[4] https://migrainefoundation.org/living-with-migraine/migraine-basics/treatment/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543882/
[6] https://drugpatentwatch.com/
[7] https://www.prnewswire.com/news-releases/lundbeck-and-otsuka-announce-fda-approval-of-vyepti-eptinezumab-aavb-for-migraine-prevention-301007209.html
[8] https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360204